Grade 2 Hand-foot Syndrom Clinical Trial
— OCRPOfficial title:
Evaluation of the Restorative Efficacy of the Cosmetic Product "Onco-Repair" vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo.
| Verified date | September 2019 |
| Source | Quanta Medical |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
| Status | Completed |
| Enrollment | 72 |
| Est. completion date | June 2, 2019 |
| Est. primary completion date | August 1, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Who suffers from grade 2 HFS - Subject under anti-tumor treatment known to cause this toxicity: targeted therapies or conventional chemotherapy: 5-Fluorouracile, Aflibercept, Axitinib, Bévacizumab, Capécitabine, Cediranib, Cytarabine, Dabrafenib, Docétaxel, Doxorubicine, Epirubicine, Pazopanib, Sorafenib, Sunitinib, Trastuzumab, Regorafenib, Vemurafenib and any other anti-tumor treatment that may lead to this toxicity - Subject 18 years old and more - Subject having been informed, having signed a free, informed and written consent - Woman of childbearing age using contraception deemed effective Non-Inclusion Criteria: - Pregnant or lactating women - Subject having a history of allergic contact dermatitis or irritation to any of the components of the investigational products - Subjects with another skin pathology that may interfere with the evaluation of a HFS (at the investigator's discretion) - Subject under anti-inflammatory treatment - Subject participating in another clinical study during the duration of the study, except in a study assessing one of the molecules listed in the section above - Subject who has already been treated for Grade 2 HFS or under other local treatment or cosmetic product - Subject refusing to interrupt the application of his/her usual care - Subject having a strongly altered general condition and / or non-autonomous subject (Karnofsky index <50%) - Subject in linguistic or psychic impossibility to understand and sign informed consent or in the impossibility of submitting to the medical follow-up of the study - Subject deprived of liberty by administrative or judicial decision, or under guardianship |
| Country | Name | City | State |
|---|---|---|---|
| France | Quanta Medical | Rueil-Malmaison |
| Lead Sponsor | Collaborator |
|---|---|
| Quanta Medical | NAOS |
France,
Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257-71. doi: 10.1159/000258880. Epub 2009 Nov 16. Review. — View Citation
Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011 Jun;137(6):953-7. doi: 10.1007/s00432-010-0958-9. Epub 2010 Nov 27. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall success | A subject is considered to have attained success if he achieves at least one grade improvement in HFS for the most affected palmer face according to the National Cancer Institute CTCATE V5.0 at any time during study period (28 days). The subjects will be defined in success or failure according to the following rules: Success: switch from grade 2 to grade 1 or grade 0 Failure: switch from grade 2 to grade 3 If subjects remain at grade 2 at the end of the study, they will be classified as either success or failure according to the evolution of clinical signs and / or quality of life assessed using the Dermatological Life Quality Index (DLQI) scale from D0 to D28. |
28 days | |
| Secondary | Time to onset of grade 1 or 0 will be assessed using time (in days) from study commencement (inclusion, D0) to first occurrence of grade 1 or lower HFS according to the CTCAEV5.0 | Time to onset of grade 1 or 0 will be assessed using time (in days) from study | 28 days | |
| Secondary | Clinical parameters such as lesion color | Clinical parameters such as lesion color will be assessed On e-CRF at D0, D7 and D28 from D0 to D28 using a standardized diary completed by subjects |
Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Clinical parameters such as presence of blisters | Clinical parameters such as presence of blisters will be assessed On e-CRF at D0, D7 and D28 from D0 to D28 using a standardized diary completed by subjects |
Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Clinical parameters such as fissures/cracks | Clinical parameters such as fissures/cracks will be assessed On e-CRF at D0, D7 and D28 from D0 to D28 using a standardized diary completed by subjects |
Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Assessment of quality of life from D0 to D28 using Dermatology Life Quality Index scale | Quality of life will be assessed from D0 to D28 using Dermatology Life Quality Index scale. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages. Meaning of Dermatology Life Quality Index scale Scores: 0 to 1 = no effect at all on patient's life 2 to 5 = small effect on patient's life 6 to 10 = moderate effect on patient's life 11 to 20 = very large effect on patient's life 21 to 30 = extremely large effect on patient's life |
28 days | |
| Secondary | Assessment of symptoms | Such as intensity of lesions, feeling of subjects, etc will be assessed: on e-CRF at D0, D7 and D28, from D0 to D28 using a standardized diary completed by subjects | Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Assessment of pain score and prurit at D0, D7 and D28 using a 100 Visual Analogue Scale [Visual analogue scale, 0 (no pain, no prurit) and 100 (worst possible pain or prurit)] | Pain score and prurit will be assessed at D0, D7 and D28 using a 100 Visual Analogue Scale [Visual analogue scale , 0 (no pain, no prurit) and 100 (worst possible pain or prurit)] | Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Assessment of the repair quality of skin | The repair quality of skin will be assessed from D0, D7 and D28 using a standardized diary completed by subjects. | Day 0 (inclusion) , Day 7 and Day 28 | |
| Secondary | Cosmetic parameters such as nourishing power of the cream will be assessed at D28 using a standardized diary | Nourishing power will be assessed at D28 using a standardized diary completed by subjects. | 28 days | |
| Secondary | Cosmetic parameters such as soothing power of the cream will be assessed at D28 using a standardized diary | Soothing power will be assessed at D28 using a standardized diary completed by subjects. | 28 days | |
| Secondary | Cosmetic parameters such as penetration power of the cream will be assessed at D28 using a standardized diary | Penetration power will be assessed at D28 using a standardized diary completed by subjects. | 28 days | |
| Secondary | Assessment of compliance | The compliance will be assessed at the end of the study: subject will be considered to be compliant if he/she applied at least the theoretical consumption of 60% of the product. | 28 days | |
| Secondary | The overall tolerance will be assessed by the investigator (Subject interrogation). This evaluation will be carried out during visits using the following rating: 1 = Very good tolerance 2 = Good tolerance 3 = Middle tolerance 4 = Poor tolerance | = Very good tolerance: no functional signs of discomfort and no objective signs during examination = Good tolerance: some functional signs of minimal and transient discomfort that did not interrupt the applications and no objective signs during examination = Middle tolerance: functional signs of discomfort, net or persistent, or objective signs during examination that did not interrupt the applications of the investigationalproduct = Poor tolerance: functional and / or objectives signs leading to discontinuation of the use of the investigational product |
28 days | |
| Secondary | Safety will be will be evaluated in terms of: - the number of subjects presenting during the study period at least : One AE/ One SAE - the total number of AEs during the study period - the total number of SAEs during the study period | Safety will be assessed on the basis of adverse event (AE) reports | 28 days |